The Brazilian Ministry of Health has announced a national protocol integrating the Fecal Immunochemical Test, known as FIT, into the Unified Health System (SUS) for asymptomatic adults aged 50 to 75. Offering a sensitivity rate between 85% and 92%, the home-collected screening kit targets the early detection of colorectal cancer.
Colorectal cancer remains the second most frequent malignancy in Brazil when excluding non-melanoma skin tumors. According to data from the National Cancer Institute (INCA), the estimated incidence sits at 53.8 thousand new cases for each year of the 2026-2028 triennium. By rolling out this protocol, public health officials aim to expand preventative access for more than 40 million Brazilians, shifting intervention upstream before symptomatic clinical presentations emerge.
How the FIT Protocol Works and Why Specificity Matters
The Fecal Immunochemical Test represents a technical evolution from older fecal occult blood tests. Unlike older methods, FIT utilizes targeted antibodies designed specifically to identify human blood.
Patients receive a dedicated sampling kit for home use, which eliminates the need for strict pre-test dietary modifications or complex bowel preparations. The test requires only a single stool sample collected by the patient and subsequently dispatched to a laboratory for analysis. When the assay detects occult bleeding—microscopic traces invisible to the naked eye—it signals the potential presence of polyps, pre-cancerous lesions, or cancer in the intestine.
Patients with positive findings are systematically triaged for further diagnostic evaluation. The clinical standard-of-care subsequent to a positive FIT remains colonoscopy, an endoscopic procedure that allows for direct visualization of the colon and rectum and the removal of polyps during the procedure, avoiding that some lesions evolve into cancer.
In Plain English: The Clinical Takeaway
- Target Population: Asymptomatic men and women between the ages of 50 and 75.
- Convenience: Home-based sampling that requires no dietary restrictions or bowel preparation prior to collection.
- Pathways: A positive screening result triggers a referral for complementary exams, such as colonoscopy.
Epidemiological Impact
By offering a less invasive initial option with a high sensitivity profile—documented between 85% and 92% by the Ministry of Health—the SUS protocol aims to increase population adherence.
| Parameter | Fecal Immunochemical Test (FIT) | Diagnostic Colonoscopy |
|---|---|---|
| Primary Role | Population-wide screening for occult blood | Direct visualization and removal of polyps |
| Patient Preparation | None required (no diet or bowel prep) | Requires bowel preparation |
| Invasiveness | Non-invasive (home collection) | Invasive procedure |
Looking Forward
The nationwide deployment of the FIT protocol across the SUS marks a shift in Brazil’s approach to oncology prevention. By streamlining early detection for millions of citizens, public health agencies hope to catch lesions at a treatable stage, thereby altering the epidemiological trajectory of colorectal cancer.
References
- Ministério da Saúde / INCA.
